On October 19, 2023 Shenzhen Ascentawits Pharmaceuticals , Ltd (hereinafter referred to as "Ascentawits" or "the Company") reported that the company will release the preclinical research results of AST-3424 for the treatment of tumors carrying DNA damage repair pathway gene mutations at the 2023 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Conference held from the 20th to the 24th of this month, laying a solid foundation for the precision treatment of AST – 3424 (Press release, Ascentawits Pharmaceuticals, OCT 19, 2023, View Source [SID1234650304]) .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through theoretical innovation, the company has developed the world’s first innovative drugs at brand-new targets, and has reserved multiple candidate compounds on the two technology platforms of " AKR1C3 enzyme-activated prodrug" and "hypoxia-activated prodrug" with independent intellectual property rights, and has preliminarily determined the efficacy in clinical studies. Among them, the company’s first product AST-3424 is an AKR1C3-activated prodrug that releases a cytotoxic dialkylated group after being activated by tumor-specific AKR1C3. AST-3424 is currently undergoing Phase II clinical studies in China and the United States. In the poster paper published at this ESMO (Free ESMO Whitepaper) conference, we explored the important role of DNA repair in the in vitro and in vivo pharmacological activity mediated by AST-3424.

Dr. Duan Jianxin, Chairman of Aixindawei, pointed out that since its establishment, the company has always adhered to the principle of independent originality, and has developed new targets based on clinical needs. Among them, AST-3424 is a world-first targeted small molecule conjugated anti-cancer drug originally developed by our team. The current Phase II clinical trial is progressing smoothly. The research results released this time prove that DNA damage repair gene mutations play an important role in both the in vitro biological activity and in vivo anti-tumor activity mediated by AST-3424. The preclinical data provided in this study will provide important support for the company’s subsequent clinical exploration of new methods for treating cancer.

Poster presentation time : October 22 , 2023 ( Spanish time )

Poster title: 20P – The essential role of DNA repair in the pharmacological activities of AST-3424

Poster No.: 20 pages

Poster presenter: Meng Fanying Shenzhen Aixindawei Pharmaceutical Technology Co., Ltd.